Department of Orthopedics, Hässleholm and Kristianstad Hospitals, SE-28125 Hässleholm, Sweden.
BMC Musculoskelet Disord. 2010 Apr 21;11:76. doi: 10.1186/1471-2474-11-76.
Patients with idiopathic carpal tunnel syndrome (CTS) are commonly treated with steroid injection into or proximal to the carpal tunnel. However, evidence for its efficacy beyond one month has not been established in randomized placebo-controlled trials. The primary aim of this randomized trial is to assess the efficacy of steroid injection into the carpal tunnel in relieving symptoms of CTS in patients with symptoms of such severity to warrant surgical treatment but have not been treated with steroid injection.
METHODS/DESIGN: The study is a randomized double-blind placebo-controlled trial. Patients referred to one orthopedic department because of CTS are screened. Eligibility criteria are age 18 to 70 years, clinical diagnosis of primary idiopathic CTS and abnormal nerve conduction tests or clinical diagnosis made independently by two orthopedic surgeons, failed treatment with wrist splinting, symptom severity of such magnitude that the patient is willing to undergo surgery, no severe sensory loss or thenar muscle atrophy, and no previous steroid injection for CTS. A total of 120 patients will be randomized to injection of 80 mg Methylprednisolone, 40 mg Methylprednisolone, or normal saline, each also containing 10 mg Lidocaine. Evaluation at baseline and at 5, 10, 24 and 52 weeks after injection includes validated questionnaires (CTS symptom severity scale, QuickDASH and SF-6D), adverse events, physical examination by a blinded assessor, and nerve conduction tests. The primary outcome measures are change in the CTS symptom severity score at 10 weeks and the rate of surgery at 52 weeks. The secondary outcome measures are the score change in the CTS symptom severity scale at 52 weeks, time to surgery, and change in QuickDASH and SF-6D scores and patient satisfaction at 10 and 52 weeks. The primary analysis will be carried out using mixed model analysis of repeated measures.
This paper describes the rationale and design of a double-blind, randomized placebo-controlled trial that aims to determine the efficacy of two different doses of steroid injected into the carpal tunnel in patients with moderately severe idiopathic CTS.
Clinicaltrials.gov identifier NCT00806871.
患有特发性腕管综合征(CTS)的患者通常接受类固醇注射到腕管内或腕管近端进行治疗。然而,随机安慰剂对照试验并未证实其在一个月以上的疗效。本随机试验的主要目的是评估类固醇注射到腕管内缓解症状的疗效CTS 患者的症状严重到需要手术治疗但尚未接受类固醇注射治疗。
方法/设计:该研究是一项随机双盲安慰剂对照试验。由于 CTS 而被转诊到一家骨科部门的患者进行了筛选。入选标准为年龄 18 至 70 岁,临床诊断为原发性特发性 CTS 和异常神经传导测试或由两名骨科医生独立诊断,腕夹板治疗失败,症状严重程度大到患者愿意接受手术,无严重感觉丧失或鱼际肌萎缩,且无先前用于 CTS 的类固醇注射。总共 120 名患者将被随机分配到 80mg 甲泼尼龙、40mg 甲泼尼龙或生理盐水注射组,每组还含有 10mg 利多卡因。注射后 5、10、24 和 52 周的基线评估包括验证问卷(CTS 症状严重程度量表、QuickDASH 和 SF-6D)、不良事件、盲法评估者进行的体格检查以及神经传导测试。主要结局指标是 10 周时 CTS 症状严重程度评分的变化和 52 周时手术率。次要结局指标是 52 周时 CTS 症状严重程度评分的变化、手术时间以及 QuickDASH 和 SF-6D 评分的变化和患者满意度在 10 和 52 周。主要分析将使用重复测量混合模型分析进行。
本文描述了一项双盲、随机安慰剂对照试验的原理和设计,旨在确定两种不同剂量的类固醇注射到中度严重的特发性 CTS 患者腕管内的疗效。
Clinicaltrials.gov 标识符 NCT00806871。